<DOC>
	<DOCNO>NCT01007656</DOCNO>
	<brief_summary>- Study design multiple-dose , open-label study - The purpose study evaluate safety twice daily GD Antrodia camphorata administration 90 day 30 healthy adult subject . - Primary objective : The mean change baseline laboratory assessment twice daily GD Antrodia camphorata administration 90th day 30 healthy adult subject . - Secondary objective : The mean change baseline laboratory assessment twice daily GD Antrodia camphorata administration 10th , 20th , 30th , 45th 60th day 30 healthy adult subject . - Safety Measurement : - include SGOT ( AST ) , SGPT ( ALT ) , albumin , glucose , creatinine , uric acid , cholesterol , TG , r-GT , alkaline phosphatase , total bilirubin , D-Bil , BUN , TP , GLO document 1st , 10th , 20th , 30th , 45th , 60th 90th day . - vital sign ( heart rate , blood pressure , body temperature ) document 1st , 10th , 20th , 30th , 45th , 60th 90th day . - Subjects monitor throughout confinement portion study .</brief_summary>
	<brief_title>A Multiple-Dose Research Study Safety Evaluation GD Antrodia Camphorata 30 Healthy Adult Subjects</brief_title>
	<detailed_description>- Study design multiple-dose , open-label study - Antrodia camphorata prove alleviate liver injury fibrosis induce chemical reduces ALT AST accord literature . - `` GD Antrodia camphorata '' market dietary supplement . - The purpose study evaluate safety twice daily GD Antrodia camphorata administration 90 day 30 healthy adult subject . - Primary objective : The mean change baseline laboratory assessment twice daily GD Antrodia camphorata administration 90th day 30 healthy adult subject . - Secondary objective : The mean change baseline laboratory assessment twice daily GD Antrodia camphorata administration 10th , 20th , 30th , 45th 60th day 30 healthy adult subject . - Study design multiple-dose , open-label study - The study site Pingtung Christian Hospital Ruiguang Branch . - Safety Measurement : - include SGOT ( AST ) , SGPT ( ALT ) , albumin , glucose , creatinine , uric acid , cholesterol , TG , r-GT , alkaline phosphatase , total bilirubin , D-Bil , BUN , TP , GLO document 1st , 10th , 20th , 30th , 45th , 60th 90th day . - vital sign ( heart rate , blood pressure , body temperature ) document 1st , 10th , 20th , 30th , 45th , 60th 90th day . - Subjects monitor throughout confinement portion study .</detailed_description>
	<criteria>Healthy adult , age 20 40 year old Physically mentally healthy subject confirm interview , medical history , clinical examination , laboratory test , chest Xray electrocardiogram The normal range body mass index 18.5 24.9 ; body mass equal [ weight ( Kg ) ] / [ height ( ) ] 2 Normal laboratory determination result ( within normal range consider clinically significant investigator ) include : SGOT ( AST ) , SGPT ( ALT ) , albumin , glucose , creatinine , uric acid , cholesterol , TG , Î³GT , alkaline phosphatase , total bilirubin , DBil , BUN , TP , GLO , HBsAg AntiHCV . Normal hematology result ( within normal range consider clinically significant investigator ) include : hemoglobin , hematocrit , WBC count differential , RBC count platelet count . Normal urinalysis result ( within normal range consider clinically significant investigator ) include : glucose , protein , RBC , WBC , epith , cast bacteria . Female subject use adequate contraception since last menstruation plan conception study Female subject nonlactating Female subject negative pregnancy test ( urine ) within 14 day prior study Informed consent form sign A recent history drug alcohol abuse Medical history allergic asthma sensitivity analogous product A clinically significant illness within past 4 week . Evidence clinical significant renal , cardiovascular , hepatic , hematopoetic , neurological , pulmonary gastrointestinal pathology within past 4 week . Ongoing peptic ulcer constipation . Planed vaccination time course study . Participation clinical investigation last 60 day . Regular use medication last 4 week . Single use medication last one week . Blood donation 500 mL within past 12 week . Individuals judge investigator coinvestigator undesirable subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>healthy adult subject</keyword>
	<keyword>safety evaluation</keyword>
	<keyword>GD Antrodia camphorata</keyword>
</DOC>